AKEBIA THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
AKEBIA THERAPEUTICS, INC. (AKBA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $3.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $3.23M, a 20.55% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.67M, a 67.72% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.22M, a 95.69% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.68M, a 29.15% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $11.28M, a 45.12% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $7.78M, a 16.55% decline from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $9.32M, a 47.80% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $17.85M, a 21.49% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.23M 10-Q · filed 2026-08-05 | $6.89M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $3.67M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $11.28M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $3.22M 10-Q · filed 2025-11-10 | $5.90M derived: sum of 2 quarters · filed 2026-08-05 | $8.08M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $2.68M 10-Q · filed 2026-08-05 | $4.86M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $2.19M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $7.78M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $1.65M 10-Q · filed 2025-11-10 | $3.72M derived: sum of 2 quarters · filed 2025-11-10 | $6.08M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $2.07M 10-Q · filed 2025-11-10 | $4.43M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $2.36M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $9.32M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $1.82M 10-Q · filed 2024-11-07 | $5.31M derived: sum of 2 quarters · filed 2024-11-07 | $7.80M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $3.49M 10-Q · filed 2024-11-07 | $5.98M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $2.49M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $17.85M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $3.38M 10-Q · filed 2023-11-08 | $10.22M derived: sum of 2 quarters · filed 2023-11-08 | $14.75M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $6.84M 10-Q · filed 2023-11-08 | $11.38M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $4.54M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $22.73M 10-K/A · filed 2023-08-28 | |||
| 2021-09-30 | $5.59M 10-Q · filed 2022-11-03 | $12.11M derived: sum of 2 quarters · filed 2022-11-03 | $18.10M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $6.51M 10-Q · filed 2022-11-03 | $12.51M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $5.99M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $24.46M 10-K/A · filed 2023-08-28 | |||
| 2020-09-30 | $6.59M 10-Q · filed 2021-11-04 | $13.46M derived: sum of 2 quarters · filed 2021-11-04 | $18.37M derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | $6.86M 10-Q · filed 2021-11-04 | $11.78M derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $4.92M 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $11.93M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $2.61M 10-Q · filed 2020-11-05 | $4.90M derived: sum of 2 quarters · filed 2020-11-05 | $6.99M derived: sum of 3 quarters · filed 2020-11-05 | $19.05M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $2.28M 10-Q · filed 2020-11-05 | $4.38M derived: sum of 2 quarters · filed 2020-11-05 | $16.44M derived: sum of 3 quarters · filed 2020-11-05 | $18.69M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-03-31 | $2.09M 10-Q · filed 2020-11-05 | $14.16M derived: sum of 2 quarters · filed 2020-11-05 | $16.41M derived: sum of 3 quarters · filed 2020-11-05 | $18.90M derived: sum of 4 quarters · filed 2020-11-05 |
| 2018-12-31 | $12.06M 10-Q · filed 2019-05-09 | $14.31M derived: sum of 2 quarters · filed 2019-11-12 | $16.81M derived: sum of 3 quarters · filed 2019-11-12 | $19.04M 10-K · filed 2021-02-25 |
| 2018-09-30 | $2.25M 10-Q · filed 2019-11-12 | $4.75M derived: sum of 2 quarters · filed 2019-11-12 | $6.98M derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-06-30 | $2.49M 10-Q · filed 2019-11-12 | $4.73M derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-03-31 | $2.23M 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $8.87M 10-K · filed 2020-03-12 | |||
| 2016-12-31 | $5.83M 10-K · filed 2019-03-26 | |||
| 2015-12-31 | $4.71M 10-K · filed 2018-03-12 | |||
| 2014-12-31 | $6.01M 10-K · filed 2017-03-06 | |||
| 2013-12-31 | $1.56M 10-K · filed 2016-03-14 | |||
| 2012-12-31 | $122.00K 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |